Apogee Therapeutics had its Relative Strength (RS) Rating upgraded from 88 to 91 Tuesday.
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.
History shows that the market's biggest winners tend to have an RS Rating north of 80 in the early stages of their moves.
Here Are 3 Keys For Successful Stock Investing
Apogee Therapeutics has risen more than 5% past a 25.54 entry in a first-stage cup without handle, meaning it's now out of a proper buy range. Look for the stock to create a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The company posted 0% earnings growth last quarter, while sales growth came in at 0%.
The company holds the No. 273 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Halozyme Therapeutics and Sarepta Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
